Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, today announced its financial results for the third quarter ended December 31 2024.

For the third quarter of FY 2025, Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY. EBITDA was Rs. 600.2 crore in the quarter ended December 31, 2024, with EBITDA margin of 17.7%. Profit After Tax (PAT) for the quarter ended December 31, 2024 was at Rs. 3 48 crore, with PAT margin of 10.3%.

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, “We delivered strong and sustained growth this quarter, driven by robust performance across the regions. Our European business continued to perform well, while our branded markets demonstrated resilient growth. Strengthening our value-chain strategy, we secured MHRA authorization for WINLEVI® in the UK, marking a pivotal step in expanding our dermatology portfolio.

“Looking ahead, we expect our North America business to gain momentum from FY26 onwards, supported by our growing respiratory and injectable portfolio. Additionally, we reached a significant milestone with IGI presenting promising first clinical data from our Phase 1 study of the trispecific TREAT™ antibody, ISB 2001, at the 66th American Society of Hematology (ASH) Annual Meeting. We continue to explore strategic partnerships to advance this asset.” he added.